Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TROP2 TIE-ADC
- Development stage
- Preclinical
- Lead developer
- TRIO Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TROP2 TIE-ADC is a dual-targeting antibody-drug conjugate (ADC) currently in development by Trio Biotech for the treatment of solid tumors, including triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). The drug is built upon Trio Biotech's proprietary Tumor Immunity Enhancing (TIE) platform, which is designed to deliver a cytotoxic payload to TROP2-expressing tumor cells while simultaneously modulating the tumor microenvironment to enhance anti-tumor immune responses. This dual-mechanism approach aims to overcome the limitations of traditional ADCs by combining direct cell killing with immune system activation. The candidate is currently in the IND-enabling (Pre-IND) stage of development.
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on TROP2 TIE-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TROP2 TIE-ADC.